Anti-KLHL20 antibody produced in rabbit

The gene KLHL20 (kelch like family member 20) is mapped to human chromosome 1q25.1. The encoded protein localizes to the trans-Golgi network (TGN). Small amount of the protein is also present in PML-NBs (promyelocytic leukemia - nuclear bodies). KLHL20 belongs to the BTB (broad-complex, tramtrack, and bric-à-brac) family of proteins.

Kelch-like protein 20 recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

KLHL20 (kelch like family member 20) is a substrate adaptor of cullin3 (Cul3). It is required for post-Golgi trafficking. The Cul3-KLHL20 complex works as an ubiquitin E3 ligase and is responsible for polyubiquitination of coronin-7, thereby targeting coronin-7 to trans-Golgi network. KLHL20 is also involved in autophagy by regulating autophagy-associated degradation of ULK1 (unc-51 like autophagy activating kinase 1) and VPS34 (vacuolar protein sorting 34) complex subunits. Additionally, KLHL20 is associated with hypoxia responses and tumorigenesis. HIF1 (hypoxia inducible factor 1)-mediated upregulation of KLHL20 gene causes hypoxia-induced PML (promyelocytic leukemia) polyubiquitination. PML destruction is linked with epithelial-mesenchymal transition, tumor growth, angiogenesis and other related events.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Corresponding Antigen APREST76532

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.